Early Outcomes of Darunavir- and/or Raltegravir-Based Antiretroviral Therapy in Children with Multidrug-Resistant HIV at a Pediatric Center in Botswana
Background: Data on the use of ritonavir-boosted darunavir (DRV/r) and/or raltegravir (RAL) in resource-limited settings are rare and there is currently no published data regarding their use among African children. Botswana has recently made DRV/r and RAL available for patients failing second-line a...
Main Authors: | Brianna L. Kirk MD, Andres Gomila MD, Mogomotsi Matshaba MD, Marape Marape MBBCh, BAO, MPH, PhD, Dipesalema R. Joel MBBCh, BAO, BMedSc, MRCP, Gabriel Anabwani MD, Michael A. Tolle MD, MPH |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2013-03-01
|
Series: | Journal of the International Association of Providers of AIDS Care |
Online Access: | https://doi.org/10.1177/1545109712463073 |
Similar Items
-
Allergic hypersensitivity to antiretroviral drugs: etravirine, raltegravir and darunavir
by: Manuel Anastacio Sánchez-Olivas, et al.
Published: (2015-04-01) -
Revealing a safer sex option to reduce HIV risk: a cluster-randomized trial in Botswana
by: Noam Angrist, et al.
Published: (2019-05-01) -
The Prevalence and Determinants of Short Stature in HIV-Infected Children
by: Dipesalema R. Joel MBBCh, BAO, BMedSc, MRCPI, et al.
Published: (2014-11-01) -
Drug-induced hypersensitivity syndrome after initiation of darunavir and raltegravir
by: Walter de Araujo Eyer-Silva, et al. -
The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health.
by: Roger J Bedimo, et al.
Published: (2014-01-01)